Evidence map›Paper›PMID 38188684›Full record

ArticleOncology research2023

Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α.

Kuo-Shyang Jeng, Po-Yu Cheng, Yueh-Hsien Lin, Po-Chun Liu, Ping-Hui Tseng, Yu-Chao Wang, Chiung-Fang Chang, Chuen-Miin Leu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kuo-Shyang JengDivision of General Surgery, Far Eastern Memorial Hospital, New Taipei City, 22060, Taiwan.
Po-Yu ChengInstitute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei City, 11221, Taiwan.
Yueh-Hsien LinInstitute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei City, 11221, Taiwan.
Po-Chun LiuInstitute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei City, 11221, Taiwan.
Ping-Hui TsengInstitute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei City, 11221, Taiwan.
Yu-Chao WangInstitute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei City, 11221, Taiwan.
Chiung-Fang ChangDepartment of Medical Research, Far Eastern Memorial Hospital, New Taipei City, 22060, Taiwan.
Chuen-Miin LeuInstitute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei City, 11221, Taiwan.
National Yang Ming Chiao Tung University · TWFar Eastern Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Current therapies are effective for HCC patients with early disease, but many patients suffer recurrence after surgery and have a poor response to chemotherapy. Therefore, new therapeutic targets are needed. We analyzed gene expression profiles between HCC tissues and normal adjacent tissues from public databases and found that the expression of genes involved in lipid metabolism was significantly different. The analysis showed that AKR1C3 was upregulated in tumors, and high AKR1C3 expression was associated with a poorer prognosis in HCC patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAldo-Keto Reductase Family 1 Member C3Aldo-Keto ReductasesCell LineDinoprostHumansIndomethacinAKR1C3 protein, humanAldo-Keto Reductase Family 1 Member C3Aldo-Keto ReductasesDinoprostIndomethacinAldo-keto reductase family member C3Hepatocellular carcinomaProstaglandin F2 alphaProstaglandin F receptor

Identifiers

PMID38188684
PMCPMC10767238
OpenAlexW4388712513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.